{
    "Clinical Trial ID": "NCT02222922",
    "Intervention": [
        "INTERVENTION 1: ",
        "  PF-06647020 0.2 mg/kg\uff08Q3W Regimen\uff09",
        "  Participants enrolled in the dose escalation phase received PF-06647020 at 0.2 mg/kg on Day 1 of each 21-day cycle as an intravenous (IV) infusion over approximately 60 minutes on an outpatient basis. Each participant received PF-06647020 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.",
        "INTERVENTION 2: ",
        "  PF-06647020 0.5 mg/kg (Q3W Regimen)",
        "  Participants enrolled in the dose escalation phase received PF-06647020 at 0.5 mg/kg on Day 1 of each 21-day cycle as an IV infusion over approximately 60 minutes on an outpatient basis. Each participant received PF-06647020 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination."
    ],
    "Eligibility": [
        "Q2W Inclusion Criteria:",
        "  Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior lines, or recurrent advanced NSCLC having received 3 or fewer prior lines",
        "  Performance Status of 0, 1, or 2",
        "  Adequate bone marrow, kidney, and liver function",
        "  Q2W Exclusion Criteria:",
        "  OVCA pts excluded with any of the following: non-epithelial, including malignant mixed mullerian tumors, unresolved bowel obstruction",
        "  Brain metastases requiring steroids",
        "  Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start",
        "  Active and clinically significant bacterial, fungal, or viral infection",
        "  Q3W Inclusion Criteria:",
        "  Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available",
        "  Performance Status of 0 or 1",
        "  Adequate bone marrow, kidney, and liver function",
        "  Part 2 includes ovarian cancer, target expressing triple negative breast cancer and non small cell lung cancer patients",
        "  Q3W Exclusion Criteria:",
        "  OVCA pts excluded with any of the following: non-epithelial, including malignant mixed mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease, unresolved bowel obstruction",
        "  Brain metastases requiring steroids",
        "  Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start",
        "  Active and clinically significant bacterial, fungal, or viral infection"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Dose Limiting Toxicities (DLTs) - Q3W Regimen",
        "  A DLT was any of the following adverse events(AEs) in the first cycle of treatment (within 21 days of first dose or until participant received second infusion if there were treatment delays). (1)Hematologic: including Grade 4 neutropenia lasting >7 days; Febrile neutropenia; Grade >=3 neutropenic infection; Grade 4 anemia; Grade >=3 thrombocytopenia with clinically significant bleeding. (2) Hepatic, including Grade >=3 serum bilirubin, hepatic transaminase or alkaline phosphatase; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >=3.0 x upper limit of normal (ULN) concurrent with elevation in bilirubin >=2.0 x ULN; (3) Grade >=3 non-hematologic, non-hepatic major organ toxicities; delayed by >2 weeks in receiving the next scheduled cycle due to persisting toxicities attributable to PF-06647020. A participant was on study for at least 21 days to be evaluable for DLT observation, and could be replaced if they terminated study participation earlier than 21 days.",
        "  Time frame: First Cycle, Day 1 up to Day 21",
        "Results 1: ",
        "  Arm/Group Title: PF-06647020 0.2 mg/kg\uff08Q3W Regimen\uff09",
        "  Arm/Group Description: Participants enrolled in the dose escalation phase received PF-06647020 at 0.2 mg/kg on Day 1 of each 21-day cycle as an intravenous (IV) infusion over approximately 60 minutes on an outpatient basis. Each participant received PF-06647020 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.",
        "  Overall Number of Participants Analyzed: 2",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  0   0.0%",
        "Results 2: ",
        "  Arm/Group Title: PF-06647020 0.5 mg/kg (Q3W Regimen)",
        "  Arm/Group Description: Participants enrolled in the dose escalation phase received PF-06647020 at 0.5 mg/kg on Day 1 of each 21-day cycle as an IV infusion over approximately 60 minutes on an outpatient basis. Each participant received PF-06647020 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.",
        "  Overall Number of Participants Analyzed: 2",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  0   0.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/2 (0.00%)",
        "  Anaemia * 0/2 (0.00%)",
        "  Febrile neutropenia * 0/2 (0.00%)",
        "  Neutropenia * 0/2 (0.00%)",
        "  Thrombocytopenia * 0/2 (0.00%)",
        "  Pericardial effusion * 0/2 (0.00%)",
        "  Atrial fibrillation * 0/2 (0.00%)",
        "  Ear pain * 0/2 (0.00%)",
        "  Abdominal pain * 0/2 (0.00%)",
        "  Constipation * 0/2 (0.00%)",
        "  Large intestinal obstruction * 0/2 (0.00%)",
        "  Large intestinal stenosis * 0/2 (0.00%)",
        "Adverse Events 2:",
        "  Total: 0/2 (0.00%)",
        "  Anaemia * 0/2 (0.00%)",
        "  Febrile neutropenia * 0/2 (0.00%)",
        "  Neutropenia * 0/2 (0.00%)",
        "  Thrombocytopenia * 0/2 (0.00%)",
        "  Pericardial effusion * 0/2 (0.00%)",
        "  Atrial fibrillation * 0/2 (0.00%)",
        "  Ear pain * 0/2 (0.00%)",
        "  Abdominal pain * 0/2 (0.00%)",
        "  Constipation * 0/2 (0.00%)",
        "  Large intestinal obstruction * 0/2 (0.00%)",
        "  Large intestinal stenosis * 0/2 (0.00%)"
    ]
}